© 2007 European Society for Medical Oncology
in this issue |
in this issue
| The first 10% of the full text of this article appears below. |
 |
Risk of relapse and mortality after 5 years of tamoxifen |
|---|
Over half of the 15-year relapses and mortality from breast cancer occur beyond five years from diagnosis. Currently more than five years of tamoxifen is not recommended following the results from NSABP B-14 and other trials which have suggested that the agonist activity of tamoxifen becomes dominant with time and may promote tumor growth. Consequently, individualized estimates of the risk of relapse and death after 5 years of tamoxifen could
|
EGFR and KRAS mutations as criteria for treatment with TKIs |
|---|
|
Bortezomib for mantle cell lymphoma |
|---|
|
Twice-daily pain monitoring as standard clinical practice |
|---|
|
Quote |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Ann Oncol:
- Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
- HF Kennecke, IA Olivotto, C Speers, B Norris, SK Chia, C Bryce, and KA Gelmon
Ann Oncol 2007 18: 45-51.[Abstract] [FREE Full Text] - EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
- N van Zandwijk, A Mathy, L Boerrigter, H Ruijter, I Tielen, D de Jong, P Baas, S Burgers, and P Nederlof
Ann Oncol 2007 18: 99-103.[Abstract] [FREE Full Text] - A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
- A Belch, CT Kouroukis, M Crump, L Sehn, RD Gascoyne, R Klasa, J Powers, J Wright, and EA Eisenhauer
Ann Oncol 2007 18: 116-121.[Abstract] [FREE Full Text] - Twice-daily pain monitoring as standard clinical practice for inpatients at a medical oncology unit: a descriptive study
- AA Martoni, C Degli Esposti, A Cricca, G Rocchi, and S Giaquinta
Ann Oncol 2007 18: 158-162.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. M Martin-Moreno, P. Alonso, A. Claveria, L. Gorgojo, and S. Peiro Spain: a decentralised health system in constant flux BMJ, March 30, 2009; 338(mar30_1): b1170 - b1170. [Full Text]
|
|
|
|
 |
|
 C. McCabe, L. Bergmann, N. Bosanquet, M. Ellis, H. Enzmann, M. von Euler, B. Jonsson, K.-J. Kallen, D. Newling, V. Nussler, et al. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective Ann. Onc., March 1, 2009; 20(3): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Meulenbeld, L. N. van Steenbergen, M. L. G. Janssen-Heijnen, V. E. P. P. Lemmens, and G. J. Creemers Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004 Ann. Onc., September 1, 2008; 19(9): 1600 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Coleman Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75) Ann. Onc., September 1, 2007; 18(9): 1433 - 1435. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P Coleman Commentary: Is epidemiology really dead, anyway? * A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950 2000 AD' Int. J. Epidemiol., August 1, 2007; 36(4): 719 - 723. [Full Text] [PDF]
|
|